GIP and diabetes mellitus: In contrast to the case of GLP-1, no GIP receptor (GIPR) agonist is clinically utilized to date because its therapeutic potential was doubted by the observations showing impaired insulinotropic effects of GIP in individuals with diabetes [42,43,44].